Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …

Although most mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
genome are expected to be either deleterious and swiftly purged or relatively neutral, a …

Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …

Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …

Background Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a
recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (…

On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …

The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the
greatest medical challenge in decades. We provide a comprehensive review of the clinical …

Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …

We report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike ΔH69/V70
in multiple independent lineages, often occurring after acquisition of receptor binding motif …

Several vaccines against coronavirus disease 2019 (COVID-19) are on the cusp of regulatory
approval. Their safety and efficacy in older people is critical to their success. Even though …